Cargando…

Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy

We recently demonstrated that simultaneous targeting of CD137 co-stimulatory and programmed cell death 1 (PD-1) co-inhibitory molecules synergistically induced an anticancer immune response in the ID8 syngeneic orthotopic mouse ovarian carcinoma model. We further showed that the therapeutic efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Huafeng, Zhao, Likun, Hellstrom, Ingegerd, Hellstrom, Karl Erik, Guo, Yajun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2014
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063147/ https://www.ncbi.nlm.nih.gov/pubmed/25050196 http://dx.doi.org/10.4161/onci.28248

Ejemplares similares

Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin
por: Wei, Huafeng, et al.
Publicado: (2013)

Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody
por: Houot, Roch, et al.
Publicado: (2012)

Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?
por: Hsu, Andy, et al.
Publicado: (2012)

A co-stimulatory trap set by myeloid leukemia cells
por: Esendagli, Gunes
Publicado: (2013)

Co-stimulatory tumor necrosis factor ligands as adjuvants for the development of subunit-based anticancer vaccines
por: Shirwan, Haval, et al.
Publicado: (2013)

Continuous 4–1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy
por: Chacon, Jessica Ann, et al.
Publicado: (2013)

A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway
por: Nagato, Toshihiro, et al.
Publicado: (2014)

Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more
por: Turnis, Meghan E., et al.
Publicado: (2012)

Ectopic CD137 expression facilitates the escape of Hodgkin and Reed-Sternberg cells from immunosurveillance
por: Pang, Wan Lu, et al.
Publicado: (2013)

Aberrant Expressions of Co-stimulatory and Co-inhibitory Molecules in Autoimmune Diseases
por: He, Weiwei, et al.
Publicado: (2019)

Human and Mouse CD137 Have Predominantly Different Binding CRDs to Their Respective Ligands
por: Yi, Ling, et al.
Publicado: (2014)

Out of the bitter came forth sweet: Activating CD28-dependent co-stimulation via PD-1 ligands
por: Ankri, Chen, et al.
Publicado: (2014)

Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
por: Rudqvist, Nils-Petter, et al.
Publicado: (2023)

Dendritic cell-based immunotherapy in ovarian cancer
por: Coosemans, An, et al.
Publicado: (2013)

Finding a needle in a haystack: Activation-induced CD137 expression accurately identifies naturally occurring tumor-reactive T cells in cancer patients
por: Ye, Qunrui, et al.
Publicado: (2013)

HIF-1 suppresses lipid catabolism to promote cancer progression
por: Zhang, Huafeng
Publicado: (2015)

Immunotherapy: Is it different for sarcomas?
por: Cleton-Jansen, Anne-Marie, et al.
Publicado: (2012)

Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets
por: Chu, Fuliang, et al.
Publicado: (2014)

Cancer immunotherapy: Benefit and harm?
por: Characiejus, Dainius
Publicado: (2012)

Shock block for improved immunotherapy
por: Rao, Aparna, et al.
Publicado: (2012)

Connecting androgen receptor signaling and the DNA damage response: Development of new therapies for advanced prostate cancer
por: Thompson, Timothy C., et al.
Publicado: (2017)

Discovering cancer immunotherapy targets in vivo
por: Zhou, Penghui, et al.
Publicado: (2014)

Personalizing immunotherapy: Balancing predictability and precision
por: Agur, Zvia, et al.
Publicado: (2012)

Intratumoral TNFα improves immunotherapy
por: Johansson, Anna, et al.
Publicado: (2012)

Chemokine-enhanced DNA vaccination in cancer immunotherapy
por: Igoucheva, Olga, et al.
Publicado: (2013)

Radiation and immunotherapy: Renewed allies in the war on cancer
por: Seung, Steven K., et al.
Publicado: (2012)

Cancer cell associated glycans as targets for immunotherapy
por: Vankemmelbeke, Mireille, et al.
Publicado: (2015)

Pharmacological DNA demethylation: Implications for cancer immunotherapy
por: Roulois, David, et al.
Publicado: (2015)

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
por: John, Liza B, et al.
Publicado: (2013)

FIST, a sword and shield fusokine for cancer immunotherapy
por: Penafuerte, Claudia, et al.
Publicado: (2012)

New insights into the role of NK cells in cancer immunotherapy
por: Salagianni, Maria, et al.
Publicado: (2012)

DKK1 as a novel target for myeloma immunotherapy
por: Qian, Jianfei, et al.
Publicado: (2012)

Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies
por: Abate-Daga, Daniel, et al.
Publicado: (2014)

Multifunctional γδ T cells and their receptors for targeted anticancer immunotherapy
por: Scheper, Wouter, et al.
Publicado: (2013)

Cancer immunotherapy with exosomes requires B-cell activation
por: Näslund, Tanja I, et al.
Publicado: (2013)

Modifying tumor-associated macrophages: An important adjunct to immunotherapy
por: Fridlender, Zvi G, et al.
Publicado: (2013)

Macrophage-based immunotherapy for the treatment of pancreatic ductal adenocarcinoma
por: Beatty, Gregory L
Publicado: (2013)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Targeting the right regulatory T-cell population for tumor immunotherapy
por: Weiss, Vivian L., et al.
Publicado: (2012)

Immunotherapy of acute myeloid leukemia based on γδ T cells
por: Gertner-Dardenne, Julie, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_oddqkgs610l3tmc9lmm0fbe66j